eMIMS New Product
New drug - Thymoglobuline
29-Jul-08
Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart
transplantation and the treatment of steroid resistant graft rejection in renal transplantation.
Thymoglobuline is a polyclonal antibody that causes peripheral and central depletion of lymphocytes.
This depletion is thought to be the primary mechanism of immunosuppression and peripheral lymphocyte depletion can be detected as early as 24 hours after the first infusion.
Thymoglobuline should be used under strict medical supervision and prescribed by physicians with experience in using immunosuppressive agents.
View Thymoglobuline drug record
Further information: Genzyme 01865 405200
Quick search - use * for an abbreviated search, eg nico*
Tools
Related Articles
Related Guidelines
Related Drugs By Area
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
Comments
Only registered users may comment. Log in now or register for a free account.